PT2385
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206541

CAS#: 1672665-49-4

Description: PT2385 is an orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha, with potential antineoplastic activity. Upon oral administration, HIF-2alpha inhibitor PT2385 allosterically binds to HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate tumor cell growth and survival.


Chemical Structure

img
PT2385
CAS# 1672665-49-4

Theoretical Analysis

MedKoo Cat#: 206541
Name: PT2385
CAS#: 1672665-49-4
Chemical Formula: C17H12F3NO4S
Exact Mass: 383.0439
Molecular Weight: 383.34
Elemental Analysis: C, 53.27; H, 3.16; F, 14.87; N, 3.65; O, 16.69; S, 8.36

Price and Availability

Size Price Availability Quantity
10.0mg USD 150.0 Ready to ship
25.0mg USD 250.0 Ready to ship
50.0mg USD 450.0 Ready to ship
100.0mg USD 750.0 Ready to ship
200.0mg USD 1350.0 Ready to Ship
500.0mg USD 2850.0 Ready to Ship
1.0g USD 4750.0 Ready to Ship
Bulk inquiry

Synonym: PT2385; PT-2385; PT 2385;

IUPAC/Chemical Name: (S)-3-((2,2-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile

InChi Key: ONBSHRSJOPSEGS-INIZCTEOSA-N

InChi Code: InChI=1S/C17H12F3NO4S/c1-26(23,24)14-3-2-13(12-7-17(19,20)16(22)15(12)14)25-11-5-9(8-21)4-10(18)6-11/h2-6,16,22H,7H2,1H3/t16-/m0/s1

SMILES Code: CS(C(C=C1)=C2C(CC(F)(F)[C@H]2O)=C1OC3=CC(C#N)=CC(F)=C3)(=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Biological target: PT-2385 is a selective HIF-2α inhibitor with a Ki of less than 50 nM.
In vitro activity: PT2385 inhibition of HIF2α transcriptional activity in cells was evaluated by qPCR quantitation of known HIF2α target gene transcripts. Treatment of 786-O cells with PT2385 significantly reduces the levels of mRNA for CCND1, VEGF-A, GLUT1, and PAI-1 in a concentration-dependent manner (Fig. 3A). The specificity of PT2385 was further evaluated in Hep3B hepatoma cells, which accumulate both HIF1α and HIF2α proteins under hypoxia and where HIFα-specific gene regulation has been previously delineated. Treatment of Hep3B cells with PT2385 reduces hypoxia-induced expression of erythropoietin (EPO) and PAI-1, both known HIF2α target genes (26–28). Compound treatment has no effect on expression of either PGK1 or pyruvate dehydrogenase kinase 1 (PDK1) genes, which are specifically regulated by HIF1α in Hep3B cells (Fig. 3B; refs. 29, 30). Consistent with the gene expression data, PT2385 only disrupts HIF2α, but not HIF1α, heterodimerization with ARNT in Hep3B cells (Fig. 3C). PT2385 has no effect on the proliferation or viability of 786-O and A498 cells in culture at concentration as high as 10 μmol/L (Supplementary Fig. S1). This result is consistent with the observations that shRNA- or siRNA-mediated HIF2α knockdown does not affect cell proliferation in vitro. Collectively, the in vitro data indicate that PT2385 is a potent and highly selective inhibitor of HIF2α-dependent gene expression. Reference: Cancer Res. 2016 Sep 15;76(18):5491-500. http://cancerres.aacrjournals.org/lookup/pmidlookup?view=long&pmid=27635045
In vivo activity: Tumor xenografts were established in the flanks of SCID/beige mice with the 786-O and A498 RCC cell lines. When tumor size reached 200 to 300 mm3, the mice were administered PT2385 by oral gavage at indicated doses on a daily basis. In the 786-O xenograft model, both 3 and 10 mg/kg PT2385 given twice daily result in a rapid, dose-dependent tumor regression. In contrast, a multi-tyrosine kinase inhibitor, sunitnib, at 40 mg/kg given once daily produces only tumor stasis (Fig. 5A and B). In the A498 xenograft model, PT2385 induces tumor stasis at 6 mg/kg once daily and tumor regression at 20 and 60 mg/kg once daily. Sunitinib at 40 mg/kg once daily has a similar effect as the higher doses of PT2385 (Fig. 5C and D). The antitumor efficacy of PT2385 was further evaluated in a patient-derived xenograft (PDX) model. The ccRCC tumor is VHL deficient, expresses both HIF1α and HIF2α (Supplementary Fig. S5), and is derived from a patient that progressed after treatment with sunitinib and everolimus. Tumor-bearing mice were treated with 30 mg/kg of PT2385 twice daily or 40 mg/kg of sunitinib once daily. After 4 weeks, PT2385 treatment completely inhibited tumor growth, whereas sunitinib had no impact (Fig. 5E). These data indicate that PT2385 has efficacy in VHL-mutant ccRCC tumors that express both HIF1α and HIF2α proteins. Furthermore, PT2385 demonstrated superior efficacy to sunitinib in 2 of 3 models evaluated, supporting that HIF2α antagonism has broad antitumor effects beyond antiangiogenesis in ccRCC. PT2385 was well tolerated in all three models, with no weight loss or behavioral changes observed (Supplementary Fig. S6A–S6C). Reference: Cancer Res. 2016 Sep 15;76(18):5491-500. http://cancerres.aacrjournals.org/lookup/pmidlookup?view=long&pmid=27635045

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 50.0 130.43

Preparing Stock Solutions

The following data is based on the product molecular weight 383.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
In vitro protocol: 1. Wallace EM, Rizzi JP, Han G, Wehn PM, Cao Z, Du X, Cheng T, Czerwinski RM, Dixon DD, Goggin BS, Grina JA, Halfmann MM, Maddie MA, Olive SR, Schlachter ST, Tan H, Wang B, Wang K, Xie S, Xu R, Yang H, Josey JA. A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma. Cancer Res. 2016 Sep 15;76(18):5491-500. doi: 10.1158/0008-5472.CAN-16-0473. Epub 2016 Sep 6. PMID: 27635045. 2. Xie C, Gao X, Sun D, Zhang Y, Krausz KW, Qin X, Gonzalez FJ. Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro. Drug Metab Dispos. 2018 Apr;46(4):336-345. doi: 10.1124/dmd.117.079723. Epub 2018 Jan 23. PMID: 29363499; PMCID: PMC5829541.
In vivo protocol: 1. Wallace EM, Rizzi JP, Han G, Wehn PM, Cao Z, Du X, Cheng T, Czerwinski RM, Dixon DD, Goggin BS, Grina JA, Halfmann MM, Maddie MA, Olive SR, Schlachter ST, Tan H, Wang B, Wang K, Xie S, Xu R, Yang H, Josey JA. A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma. Cancer Res. 2016 Sep 15;76(18):5491-500. doi: 10.1158/0008-5472.CAN-16-0473. Epub 2016 Sep 6. PMID: 27635045. 2. Xie C, Gao X, Sun D, Zhang Y, Krausz KW, Qin X, Gonzalez FJ. Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro. Drug Metab Dispos. 2018 Apr;46(4):336-345. doi: 10.1124/dmd.117.079723. Epub 2018 Jan 23. PMID: 29363499; PMCID: PMC5829541.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

PT2385

10.0mg / USD 150.0